These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 28162854

  • 1. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
    Asgari MM, Ray GT, Geier JL, Quesenberry CP.
    J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
    [Abstract] [Full Text] [Related]

  • 2. Serious infections among a large cohort of subjects with systemically treated psoriasis.
    Dobry AS, Quesenberry CP, Ray GT, Geier JL, Asgari MM.
    J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
    [Abstract] [Full Text] [Related]

  • 3. The risk of melanoma and hematologic cancers in patients with psoriasis.
    Reddy SP, Martires K, Wu JJ.
    J Am Acad Dermatol; 2017 Apr; 76(4):639-647.e2. PubMed ID: 27876302
    [Abstract] [Full Text] [Related]

  • 4. Treatments for psoriasis and the risk of malignancy.
    Patel RV, Clark LN, Lebwohl M, Weinberg JM.
    J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
    [Abstract] [Full Text] [Related]

  • 5. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
    van Lümig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC, Fransen J, Kievit W, de Jong EM.
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
    [Abstract] [Full Text] [Related]

  • 6. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
    Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD.
    JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
    [Abstract] [Full Text] [Related]

  • 7. Personal history of psoriasis and risk of nonmelanoma skin cancer (NMSC) among women in the United States: A population-based cohort study.
    Dai H, Li WQ, Qureshi AA, Han J.
    J Am Acad Dermatol; 2016 Oct; 75(4):731-735. PubMed ID: 27436157
    [Abstract] [Full Text] [Related]

  • 8. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
    Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L, Cesame Study Group.
    Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
    [Abstract] [Full Text] [Related]

  • 9. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.
    Katz KA, Marcil I, Stern RS.
    J Invest Dermatol; 2002 Jun; 118(6):1038-43. PubMed ID: 12060400
    [Abstract] [Full Text] [Related]

  • 10. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
    Blauvelt A, Lebwohl M, Langley RG, Rowland K, Yang YW, Chan D, Miller M, You Y, Yu J, Thaҫi D, Foley P, Papp KA.
    J Am Acad Dermatol; 2023 Aug; 89(2):274-282. PubMed ID: 37019386
    [Abstract] [Full Text] [Related]

  • 11. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
    Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, Alsina M, Herrera-Ceballos E, Gómez-García FJ, Ferrán M, López-Estebaranz JL, Hernanz JM, Belinchón-Romero I, Vilar-Alejo J, Rivera R, Carrascosa JM, Carazo C.
    Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
    [Abstract] [Full Text] [Related]

  • 12. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.
    Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D.
    Br J Dermatol; 2015 Nov; 173(5):1183-90. PubMed ID: 26265015
    [Abstract] [Full Text] [Related]

  • 13. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
    Chakravarty EF, Michaud K, Wolfe F.
    J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
    [Abstract] [Full Text] [Related]

  • 14. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
    Chen Y, Friedman M, Liu G, Deodhar A, Chu CQ.
    Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
    [Abstract] [Full Text] [Related]

  • 15. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota.
    Brewer JD, Shanafelt TD, Khezri F, Sosa Seda IM, Zubair AS, Baum CL, Arpey CJ, Cerhan JR, Call TG, Roenigk RK, Smith CY, Weaver AL, Otley CC.
    J Am Acad Dermatol; 2015 Feb; 72(2):302-9. PubMed ID: 25479909
    [Abstract] [Full Text] [Related]

  • 16. Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients.
    Funk-Debleds P, Ducroux E, Guillaud O, Ursic-Bedoya J, Decullier E, Vallin M, Euvrard S, Pageaux GP, Boillot O, Dumortier J.
    J Am Acad Dermatol; 2018 Jul; 79(1):84-91. PubMed ID: 29307647
    [Abstract] [Full Text] [Related]

  • 17. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
    Yates WB, Vajdic CM, Na R, McCluskey PJ, Wakefield D.
    Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
    [Abstract] [Full Text] [Related]

  • 18. The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network.
    Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM.
    JAMA Dermatol; 2016 Mar; 152(3):282-90. PubMed ID: 26676102
    [Abstract] [Full Text] [Related]

  • 19. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
    Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L.
    J Invest Dermatol; 2003 Feb; 120(2):211-6. PubMed ID: 12542524
    [Abstract] [Full Text] [Related]

  • 20. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
    Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH.
    Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.